Vice President of Product Management, Clinical Next Generation Sequencing, Thermo Fisher Scientific
Vice President of Product Management, Clinical Next Generation Sequencing, Thermo Fisher Scientific
Associate Director, Cytogenetics & Molecular Pathology Laboratories - Department of Pathology & Laboratory Medicine - Cedars-Sinai Medical Center
Director of Molecular Pathology, Cedars-Sinai Medical Center
With traditional NGS, long turnaround times (TAT) of 4+ weeks and high failure rates due to quantity not sufficient (QNS) are common. The Ion Torrent™ Genexus™ System is a better testing solution: it decreases TAT to as little as 1 day from sample to results,* and essentially eliminates QNS failure, achieving success using tissue samples as small as 10 ng. Join us to learn how the Genexus System can improve your lab’s efficiency and increase your testing success rates.
By the conclusion of this session you will understand:
Learning Objectives:
1. Understand the value of the Genexus in a post-pandemic environment
2. Explore the financial & operational impacts of the Ion Torrent Genexus™ System for in-house
genomic profiling
This virtual meeting will be conducted within OncomineWorld in our virtual auditorium. OncomineWorld is so much more than your traditional virtual event – you can navigate to many different areas and experience a new level of virtual interactivity. Within OncomineWorld you can…
* Specimen-to-report workflow will be available after the Ion Torrent™ Genexus™ Purification System and integrated reporting capabilities are added in 2021.